IDEAYA Biosciences (IDYA) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• IDEAYA Biosciences is expected to announce its Q2 2025 earnings on August 5th, with analysts forecasting a loss of ($0.85) per share and revenue of $3.48 million.
• The company's shares opened at $25.02 on Tuesday, up 2.1%, and have a market cap of $2.19 billion.
• Recent analyst ratings for IDEAYA have been positive, with upward adjustments in price targets and a consensus rating of "Moderate Buy", alongside an average price target of $48.09.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Tuesday, August 5th. Analysts expect IDEAYA Biosciences to post earnings of ($0.85) per share and revenue of $3.48 million for the quarter.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter last year, the business posted ($0.53) EPS. On average, analysts expect IDEAYA Biosciences to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

IDEAYA Biosciences Trading Up 2.1%

NASDAQ IDYA traded up $0.51 on Wednesday, hitting $25.35. 1,775,830 shares of the company were exchanged, compared to its average volume of 926,816. The stock has a fifty day moving average of $21.85 and a 200-day moving average of $20.33. The company has a market cap of $2.22 billion, a PE ratio of -7.06 and a beta of 0.03. IDEAYA Biosciences has a 12 month low of $13.45 and a 12 month high of $44.42.

Analyst Ratings Changes

Several research analysts have weighed in on IDYA shares. The Goldman Sachs Group raised IDEAYA Biosciences to a "hold" rating and set a $25.00 price objective on the stock in a research report on Thursday, July 10th. Royal Bank Of Canada raised shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and reduced their target price for the company from $57.00 to $30.00 in a research report on Wednesday, July 9th. JPMorgan Chase & Co. increased their price target on IDEAYA Biosciences from $66.00 to $72.00 and gave the stock an "overweight" rating in a research note on Monday. Wells Fargo & Company assumed coverage on IDEAYA Biosciences in a research note on Thursday, June 26th. They issued an "overweight" rating and a $44.00 price objective on the stock. Finally, TD Cowen started coverage on shares of IDEAYA Biosciences in a research report on Tuesday, July 22nd. They set a "buy" rating for the company. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $48.09.

Institutional Trading of IDEAYA Biosciences

Several institutional investors have recently added to or reduced their stakes in IDYA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of IDEAYA Biosciences by 8.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 57,044 shares of the company's stock worth $938,000 after purchasing an additional 4,308 shares during the last quarter. Royal Bank of Canada grew its stake in shares of IDEAYA Biosciences by 30.1% during the 1st quarter. Royal Bank of Canada now owns 122,460 shares of the company's stock worth $2,006,000 after purchasing an additional 28,322 shares during the period. Finally, Millennium Management LLC grew its position in IDEAYA Biosciences by 345.2% during the first quarter. Millennium Management LLC now owns 547,637 shares of the company's stock worth $8,970,000 after buying an additional 424,625 shares during the period. Institutional investors and hedge funds own 98.29% of the company's stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.